Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company.

A number of equities research analysts have weighed in on BIOVF shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Pareto Securities cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Finally, Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd.

Swedish Orphan Biovitrum Stock Performance

OTCMKTS:BIOVF opened at $42.80 on Tuesday. The stock’s fifty day moving average is $47.10 and its 200 day moving average is $46.29. The firm has a market capitalization of $15.24 billion, a PE ratio of 95.11 and a beta of 0.47. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. Swedish Orphan Biovitrum has a fifty-two week low of $34.88 and a fifty-two week high of $49.03.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria.